Figure 5

BSNXD-treated HUVECs supernatant inhibits CCR2, LFA-1, VLA-4 expression in U937 and attenuates U937 cell adhesion. After HUVECs were treated as above, the supernatant was collected and used to treat U937 cells. CCR2 (a), LFA-1 (b) and VLA-4 (c) mRNA and protein expression levels in treated U937 cells were assessed by RT-PCR, flow cytometry and western blot. The ox-LDL-induced increase (Control group) could be inhibited by the 10% drug-derived serum. Furthermore, 10% BSNXD could suppress U937 cell adhesion; NOS inhibitor (L-NAME) and ERβ antagonist (R, RTHC) but not ERα antagonist (MPP) could block the anti-adhesion effect of the 10% drug-derived serum (d). Data are expressed as mean values±S.E.M. (n=6). *P<0.05, **P<0.01